Dallas-based UT Southwestern Medical Center has partnered with InterAct Therapeutics to develop and commercialize a gene therapy designed to treat breast cancer liver metastasis.
The partnership builds on the research of Isaac Chan, MD, PhD, assistant professor of internal medicine in the division of hematology and oncology and of molecular biology at UT Southwestern, according to a March 24 news release from the health system.
Dr. Chan serves as a co-founder and chief scientific officer of InterAct Therapeutics.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
